Mongolia has sent a list of 179 quality-compliant medicines to potential procurement partners in Poland, Türkiye and South Korea, as well as UNDP, UNOPS and UNICEF, for price proposals. The health ministry is expanding single-source and international procurement for high-cost, high-use and shortage-prone medicines identified by hospitals. Officials said MNT 209.6 billion was spent on 424 medicines in 2025. A UNDP arrangement now covers 45 medicines from ten manufacturers, while the state fully finances epilepsy medication for about 5,000 people. The ministry says reserves have been established for the contracted medicines.
M-International Editorial DeskUpdated August 20, 2026
The Ministry of Health has asked international partners and suppliers for price proposals covering 179 medicines that meet specified quality requirements. Requests were sent to Poland, Türkiye, South Korea, UNDP, UNOPS and UNICEF.
Hospitals are submitting annual forecasts for medicines with high cost, high consumption or a significant shortage risk. The ministry reported that MNT 209.6 billion was spent on 424 medicines in 2025. Current single-source arrangements include hemophilia factor, snake antivenom and targeted cancer treatments. A budget of MNT 2.7 billion for recombinant antihemophilic factor reportedly produced savings of MNT 350 million. A separate UNDP contract covers 45 medicines from ten manufacturers, and the state fully covers epilepsy medication for approximately 5,000 citizens.